Metagenomi, Inc. Common Stock
Symbol: MGX (NASDAQ)
Company Description:
Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. The genome editing toolbox includes systems for making small edits such as programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), as well as large gene integration systems including large template RIGS and CRISPR-associated transposases (CASTs). The company is focused on its vivo gene editing for its wholly-owned pipeline while pursuing technology out licensing for ex vivo cell therapy. Its pipeline includes product candidates aimed at addressing disorders like Hemophilia A (through MGX-001), Refractory Hypertension, Cardiovascular diseases, and Wilson's disease, among others.
- Today's Open: $3.1
- Today's High: $3.434
- Today's Low: $2.92
- Today's Volume: 324.56K
- Yesterday Close: $3.15
- Yesterday High: $3.38
- Yesterday Low: $3.1
- Yesterday Volume: 495.88K
- Last Min Volume: 490
- Last Min High: $2.93
- Last Min Low: $2.926
- Last Min VWAP: $2.92959
- Name: Metagenomi, Inc. Common Stock
- Website: https://metagenomi.co
- Listed Date: 2024-02-09
- Location: EMERYVILLE, CA
- Market Status: Active
- CIK Number: 0001785279
- SIC Code: 2836
- SIC description: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
- Market Cap: $125.74M
- Round Lot: 100
- Outstanding Shares: 37.53M
- Asset Type: CS
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-10-01 | 8-K | View |
| 2025-09-11 | 144 | View |
| 2025-09-02 | 4 | View |
| 2025-08-15 | 3 | View |
| 2025-08-12 | 10-Q | View |
| 2025-08-12 | 8-K | View |
| 2025-07-09 | 144 | View |
| 2025-06-12 | 4 | View |
| 2025-06-12 | 4 | View |
| 2025-06-12 | 4 | View |
| 2025-06-11 | 8-K | View |
| 2025-06-09 | 4 | View |
| 2025-06-09 | 4 | View |
| 2025-06-09 | 4 | View |
| 2025-06-09 | 4 | View |
| 2025-06-09 | 4 | View |
| 2025-05-14 | 8-K | View |
| 2025-05-13 | 10-Q | View |
| 2025-05-13 | 8-K | View |
| 2025-04-28 | ARS | View |